Overview

Improve PAD PERformance With METformin

Status:
Recruiting

Trial end date:
2024-09-30

Target enrollment:

Participant gender:

Summary

The PERMET trial will determine whether metformin daily for six months improves six-minute walk performance in individuals with peripheral artery disease compared to placebo.

Phase:

Phase 3

Details

Lead Sponsor:

Northwestern University

Treatments:

Metformin